Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Aclaris Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
1.68
6.15
4.23
6.48
6.76
29.8
31.2
18.7
7.83
Cost of revenue
1.21
4.33
4.06
5.13
4.71
4.02
3.42
2.79
2.09
Gross profit
0.48
3.24
0.17
1.35
2.05
25.7
27.8
15.9
5.74
Research and development
33.5
35.8
60.8
64.2
29.3
43.8
77.8
98.4
33.6
52.6
Selling and marketing
3.3
0.09
0.17
0.67
General and administrative
11.8
18.9
25.8
27.8
20.5
23.6
25.1
32.4
22.2
22
Operating expenses
48.6
72.9
139
Operating income
-48.6
-54.4
-84.8
-111
-50.9
-89.7
-89.9
-97.4
-142
-76.4
Interest income
8.51
7.95
7.64
Other non-operating income
0.49
2.07
2.68
-2.48
-0.42
-1.14
2.95
8.51
9.87
11.5
Pre-tax income
-48.1
-70.4
-82.1
-114
-51.3
-90.9
-86.9
-88.8
-132
-64.9
Income tax
-1.83
-0.18
-0.37
Income from continuing operations
-52.3
-82.1
-114
-51.2
-90.9
-86.9
Net income
-48.1
-68.5
-133
-161
-51
-90.9
-86.9
-88.5
-132
-64.9
EBITDA
-48.4
-54
-82.9
-105
-49.6
-88.8
-89.1
-96.5
-141
-75.9
EPS, basic
-2.25
-2.44
-4.03
-3.90
-1.20
-1.60
-1.33
-1.27
-1.71
-0.53
EPS, diluted
-2.25
-2.44
-4.03
-3.90
-1.20
-1.60
-1.33
-1.27
-1.71
-0.53
Shares, basic (weighted)
21.4
28.1
32.9
41.3
42.5
56.7
65.2
69.8
77.3
123
Shares, diluted (weighted)
21.4
28.1
32.9
41.3
42.5
56.7
65.2
69.8
77.3
123
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
30.2
20.2
57
34.2
22.1
27.3
45.3
39.9
24.6
20
Short-term investments
107
174
111
39.1
32.1
164
172
79.2
89
70.8
Receivables
0.48
0.56
0.7
0.77
0.62
0.48
0.3
0.32
Inventory
0
0.79
0
Other current assets
1.33
5.88
4.8
3.12
2.59
13
13.5
9.45
12
Total current assets
139
200
179
83.8
57.5
205
232
129
126
96.3
Property, plant and equipment
0.48
2.16
2.29
2.47
1.65
1.34
1.1
1.62
1.01
0.76
Goodwill
18.5
18.5
Intangible assets
7.35
7.27
7.2
7.12
7.05
6.97
0.27
Long-term investments
36.9
15
34.2
12.2
62.8
90.3
60.6
Other non-current assets
0.14
0.28
0.33
4.83
4.51
3.55
2.73
4.16
3.07
2.77
Total assets
176
244
276
98.3
70.8
251
255
197
220
160
Accounts payable
2.85
7.82
11.7
9.92
5.25
9.99
10.4
8.88
4.69
13.2
Accrued liabilities
3.38
4.94
8.09
7.72
5.91
10.1
8.7
19.4
20.3
8.79
Deferred revenue
3.89
3.94
Total current liabilities
6.22
12.8
27.3
22.4
14.9
22.9
21.9
31
31.6
28.6
Lease liabilities
3.55
2.89
2.15
1.57
3.07
2.12
1.57
Other non-current liabilities
0.37
0.56
0.48
3.74
3.18
2.17
1.57
3.07
4.44
1.57
Total liabilities
6.6
18.2
60.4
28.4
33.1
53.9
57
40.2
64.8
57.4
Total debt
29.9
10.7
Paid-in capital
261
385
507
524
542
793
881
928
1,058
1,070
Retained earnings
-90.9
-159
-292
-454
-505
-595
-682
-771
-903
-968
Other comprehensive income
-0.27
-0.25
-0.07
-0.07
-0.09
-0.22
-0.9
-0.11
0.1
0.61
Shareholders' equity
169
225
215
69.9
37.7
197
198
157
156
103
Total equity
169
225
215
69.9
37.7
197
198
157
156
103
Total liabilities and equity
176
244
276
98.3
70.8
251
255
197
220
160
Shares outstanding
26.1
30.9
41.2
41.5
45.1
61.2
66.7
70.9
108
120
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-48.1
-68.5
-133
-161
-51
-90.9
-86.9
-88.5
-132
-64.9
Depreciation and amortization
0.12
0.4
1.88
6.41
1.32
0.92
0.8
0.86
0.81
0.45
Stock-based compensation
6.1
14.4
20.1
16.2
11.2
14.1
15
20.5
10.9
12.4
Deferred income tax
-1.84
-0.18
-0.37
Change in receivables
-4.38
-0.81
4.9
0.15
0.14
0.19
-0.02
Change in inventory
0.1
0.61
Change in payables
1.81
4.56
6.96
-3.16
-5.22
3.66
0.37
-1.47
-4.19
8.45
Cash from operations
-34.6
-54.7
-101
-96.4
-38.6
-52.1
-67.6
-78.3
-20.1
-47.1
Capital expenditures
-0.23
-1.24
-1.36
-1.61
-0.45
-0.31
-0.61
-1.31
-0.12
-0.11
Acquisitions
-9.65
Purchases of investments
-149
-197
-162
-137
-47.7
-235
-165
-136
-120
-39.7
Sales and maturities of investments
87.1
153
239
210
54.6
67.8
178
183
86.1
89
Cash from investing
-61.9
-55.7
9.37
106
6.39
-168
12.6
46.2
-69.8
48.4
Debt issued
29.9
10.9
Stock issued
98.2
0.24
0.58
0.21
0.07
1.46
0.16
0.09
0.03
Cash from financing
117
100
128
-30.3
18.4
225
72.9
26.7
74.5
-5.86
Net change in cash
20.3
-9.97
36.8
-21.1
-13.9
5.29
17.9
-5.4
-15.3
-4.61
Free cash flow
-34.8
-55.9
-102
-98.1
-39.1
-52.4
-68.2
-79.6
-20.2
-47.2
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $5.15 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
79.5%
Gross profit / revenue.
Operating margin
-1,050.0%
Operating income / revenue.
EBITDA margin
-1,045.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-921.5%
Net income / revenue.
FCF margin
-756.5%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-755.1%
Cash from operations / revenue.
Return on equity (ROE)
-60.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-42.1%
Net income / average total assets.
Return on invested capital (ROIC)
-64.7%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
770.6%
Research and development expense / revenue.
Stock-based pay / revenue
141.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.4%
Capital expenditures / revenue.
D&A / revenue
5.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-58.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-35.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
3.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-64.0%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-39.4%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
33.6%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-33.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-19.5%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
22.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-27.2%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-14.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
17.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
58.6%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
23.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
23.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.46x
Current assets / current liabilities.
Quick ratio
3.24x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.24x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.06
Revenue / diluted weighted shares.
FCF per share
-$0.44
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.43
Cash from operations / diluted weighted shares.
Book value per share
$0.89
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
92.2x
Market cap / revenue.
P/B
6.08x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
6.08x
Market cap / tangible book value, when positive.
EV/Sales
81.1x
Enterprise value / revenue.
FCF yield
-8.2%
Free cash flow / market cap.
Earnings yield
-10.0%
Net income / market cap (the inverse of P/E).
What was Aclaris Therapeutics, Inc.'s revenue in fiscal 2025?
Aclaris Therapeutics, Inc. reported revenue of $7.8M for fiscal 2025, 58.2% lower than the year before.
Was Aclaris Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $64.9M.
How much free cash flow did Aclaris Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $47.1M minus capital expenditures of $111.0K left free cash flow of -$47.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.